Literature DB >> 30191001

Isoform-specific activation of Akt involvement in hepatocarcinogenesis.

Mohamed R Imache1,1, Jean-Michel Pawlotsky1,2,3,1,2,3, Hervé Lerat1,3,1,3.   

Abstract

Entities:  

Keywords:  AKT; HCC; HCV; cancer; isoform; liver

Year:  2015        PMID： 30191001      PMCID： PMC6095155          DOI： 10.2217/hep.15.19

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


× No keyword cloud information.
  28 in total

1.  The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.

Authors:  Y Rebecca Chin; Alex Toker
Journal:  Mol Cell       Date:  2010-05-14       Impact factor: 17.970

2.  Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.

Authors:  Ioanna G Maroulakou; William Oemler; Stephen P Naber; Philip N Tsichlis
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

3.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Authors:  Sandrine Boyault; David S Rickman; Aurélien de Reyniès; Charles Balabaud; Sandra Rebouissou; Emmanuelle Jeannot; Aurélie Hérault; Jean Saric; Jacques Belghiti; Dominique Franco; Paulette Bioulac-Sage; Pierre Laurent-Puig; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

4.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene.

Authors:  W S Chen; P Z Xu; K Gottlob; M L Chen; K Sokol; T Shiyanova; I Roninson; W Weng; R Suzuki; K Tobe; T Kadowaki; N Hay
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

Review 5.  Akt1 and Akt2: differentiating the aktion.

Authors:  Lisa Heron-Milhavet; Nabil Khouya; Anne Fernandez; Ned J Lamb
Journal:  Histol Histopathol       Date:  2011-05       Impact factor: 2.303

6.  AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.

Authors:  Coral Ho; Chunmei Wang; Sandra Mattu; Giulia Destefanis; Sara Ladu; Salvatore Delogu; Julia Armbruster; Lingling Fan; Susie A Lee; Lijie Jiang; Frank Dombrowski; Matthias Evert; Xin Chen; Diego F Calvisi
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

7.  Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions.

Authors:  Takashi Katome; Toshiyuki Obata; Rie Matsushima; Norihisa Masuyama; Lewis C Cantley; Yukiko Gotoh; Kazuhiro Kishi; Hiroshi Shiota; Yousuke Ebina
Journal:  J Biol Chem       Date:  2003-05-06       Impact factor: 5.157

8.  The Akt isoforms are present at distinct subcellular locations.

Authors:  Stacey A Santi; Hoyun Lee
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-16       Impact factor: 4.249

9.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

10.  Opposing functions of Akt isoforms in lung tumor initiation and progression.

Authors:  Nicolle M Linnerth-Petrik; Lisa A Santry; James J Petrik; Sarah K Wootton
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240
View more
  1 in total

Review 1.  The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis.

Authors:  Abdulrahman Alwhaibi; Arti Verma; Mir S Adil; Payaningal R Somanath
Journal:  Pharmacol Res       Date:  2019-05-09       Impact factor: 7.658
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.